Northwestern Cancer Prevention Consortium

Project: Research project

Description

Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials;

Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints.

Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.
StatusActive
Effective start/end date9/3/197/31/24

Funding

  • National Cancer Institute (NOT SPECIFIED)

Fingerprint

Clinical Trials
Neoplasms
Oncogenes
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Cell Proliferation
Apoptosis
Safety